Not provided
Not provided
Not provided
Not provided
All clinicial studies were stopped during the Covid-19 pandemic. Interventions not possible to perform, neither at workplace nor at the gym.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Uppsala University Hospital | OTHER |
| AFA Insurance | INDUSTRY |
| The Swedish Research Council | OTHER_GOV |
| Uppsala County Council, Sweden |
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate whether a vocational behaviour change ability programme has any additional effect on return to work compared with return to work coordination only in persons with chronic pain.
New vocational rehabilitation models including the workplace are urgently needed for persons with chronic pain.
Return to work coordination means external and internal coordination regarding sick leave by help of a rehabilitation coordinator from health care. The goal is to establish a common return to work plan between employer and employee as dictated by Swedish law. The hypothesis is that return to work coordination is not sufficient. Additional effects on return to work and work ability from a behaviour change ability programme aiming to enhance work ability by targeting context at the workplace, physical and psychological functioning, and behavioral skills at work are expected.
The hypothesis is tested in a randomised controlled trial. Before the start of the trial a series of 3-6 experimental single case studies will be performed to study the implementation of the interventions more thoroughly.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Comparison intervention | Active Comparator | Return To Work Coordination: external and internal coordination regarding sick leave. Establishment of a common return to work plan between employer and employee. |
|
| Experimental intervention | Experimental | Return To Work Coordination + Behaviour Change Ability Programme Behaviour Change Ability Programme:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Return To Work Coordination | Other | External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Return to work | Average sick leave according to the Swedish Social Insurance registry, defined as net days. | Number of days during a 12-month period from baseline to 12 months post baseline. |
| Work ability | Self-report. Work Ability Index (WAI). The questionnaire covers 7 dimensions:
The dimensions have different scores. A total index is computed ranging from 7 to 49, where higher scores indicate higher work ability. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Work Ability | Self-report. Work Ability Index (WAI). The questionnaire covers 7 dimensions:
The dimensions have different scores. A total index is computed ranging from 7 to 49, where higher scores indicate higher work ability. |
| Measure | Description | Time Frame |
|---|---|---|
| Patient-specific goals for return to work | Patient Goal Priority Questionnaire (PGPQ-WORK). Patient-specific questionnaire where the participant list 1-3 work-related activities that he or she wish to be able to perform better as a result of treatment. Activity, self-efficacy, fear of performance, and expected outcome level is then rated for each activity separately on 4 11-point numerical rating scales where higher scores indicate worse outcomes. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pernilla Åsenlöf, Professor | Department of Neuroscience, Uppsala University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Uppsala University Hospital | Uppsala | Uppland | 75226 | Sweden |
The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D059350 | Chronic Pain |
| D004715 | Endometriosis |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| OTHER_GOV |
Not provided
Not provided
Not provided
The outcomes assessors are blinded to study condition during all measurements. Participants and providers of the return to work coordination intervention are blinded until a rehabilitation plan has been completed. Thereafter allocation to study condition is disclosed and the other components of the behaviour change ability programme are provided to those in the experimental group.
| Behaviour Change Ability Program | Behavioral |
|
|
| Baseline, 6 months, 24 months |
| Return to work | Average sick leave according to the Swedish Social Insurance registry, defined as net days. | Baseline, 6 months, 24 months |
| Short-term sick leave < 2 weeks, number of days | Self-reported number of days with sick-leave not exceeding two weeks | 6 months, 12 months, 24 months |
| Health-related quality of life: EQ-5D | Self-report. The EuroQoL - Five dimension (EQ-5D). The five dimensions are: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each scales ranges from 0 to 2, where a low score indicates better health. The EQ-5D questionnaire also includes a visual analog scale where perceived health status is rated with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status). | Baseline, 6 months, 12 months, 24 months |
| Opioid use | Interview: Time-Line-Follow-Back. 4-week recall regarding opioid medication yes/no and dose. | Baseline, 6 months, 12 months, 24 months |
| Substance use disorder | Interview: Mini International Neuropsychiatric Interview, Part J (Substance use). Response format yes/no. Mild substance use disorder = 2-3 symptoms Moderate substance use disorder = 4-5 symptoms Severe substance use disorder = 6 or more symptoms | Baseline, 6 months, 12 months, 24 months |
| Pain severity: The Brief Pain Inventory | Self-report. The Brief Pain Inventory. Severity is measured with 4 items where worst, least, average, and current pain during the past week are scored. Each scale ranges from 0-10, where 0 = 'no pain' and 10 = 'pain as bad as can be'. Each of the severity scales will be presented separately. | Baseline, 6 months, 12 months, 24 months |
| Pain interference: The Brief Pain Inventory | Self-report. The Brief Pain Inventory. Interference is measured with 7 items (general activity, mood, working ability, normal work, relations with other people, sleep, and enjoyment of life). Each scale ranges from 0 to 10, where 0 ='does not interfere', and 10 = 'completely interferes'. Interference is scored as the mean of the seven interference items. Higher scores indicate higher pain interference. | Baseline, 6 months, 12 months, 24 months |
| Balance | The MiniBESTest | Baseline, 6 months, 12 months |
| Functional lifting capacity | Progressive Isoinertial Lifting Evaluation (PILE): cervical lifting test | Baseline, 6 months, 12 months |
| Grip strength | Dynamometer GRIPPIT (name of brand) | Baseline, 6 months, 12 months |
| Catastrophizing | Self-report, The Pain Catastrophizing Scale (PCS) - Swedish version. 13 items, ranging from 0 to 4 where 0 = 'not at all', 4 = 'all the time'. A total score is calculated ranging from 0 to 52 where higher scores indicate higher catastrophizing. | Baseline, 6 months, 12 months |
| Fear of movement and reinjury | Self-report, The Tampa Scale of Kinesiophobia-11 (TSK-11), Swedish version. 11 items ranging from 1 to 4 where 1 = 'does not agree at all', 4 = 'totally agree'. A total score is calculated ranging from 11 to 44 where higher scores indicate higher fear of movement/kinesiophobia. | Baseline, 6 months, 12 months |
| Psychological inflexibility in pain | Self-report. Psychological inflexibility in pain (PIPS) is a 12-item scale used to assess psychological inflexibility (i.e. avoidance, acceptance, fusion, values orientation, dirty discomfort) in people with chronic pain. Two main components are measured: 1) Avoidance of pain (items: 1,2,4,5,7,8,10,11), 2) Fusion with pain thoughts (items: 3,6,9,12) Scoring: Respondents are asked to rate items on a 7-point scale that ranges from 1= 'never true' to 7 = 'always true'. Scores are summed to a total score and to two subscale scores. Higher scores indicate greater levels of psychological inflexibility. | Baseline, 6 months, 12 months |
| Depressive symptoms | Self-report: Patient Health Questionnaire - 9 (PHQ-9), Swedish version. 9 items ranging from 0 ='not at all', to 3 ='almost every day'. 1 item ranging from 0 ='no difficulties, to 3 = 'extreme difficulties'. The first 9 items are summed to a sum score ranging from 0 to 27, where: 0-4 = no signs of depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, 20-27 = severe depression. Item 10 is reported as a single item where high scores indicate high interference with daily function. | Baseline, 6 months, 12 months, 24 months |
| Generalised Anxiety Disorder | Self-report: Generalised Anxiety Disorder (GAD-7). 7 items ranging from 0 ='not at all', to 3 ='almost every day'. 1 item ranging from 0 ='no difficulties, to 3 = 'extreme difficulties'. 1 item ranging from 0 ='not at all, to 3 = 'very disturbing'. The first 7 items are summed to a sum score ranging from 0 to 21, where: 0-4 = no signs of anxiety, 5-9 = mild GAD, 10-14 = moderate GAD, 15-21 = severe GAD. Item 8 is reported as a single item where higher score means higher interference. | Baseline, 6 months, 12 months, 24 months |
| Experience of injustice | Self-report: Injustice Experience Questionnaire (IEQ), Swedish version. 12 items ranging from 0 ='never, to 4 ='all the time'. A total score is computed by summing the scores to all 12 items, ranging from 0-48 where higher scores indicate higher experience of injustice. Two subscales is used. 1) Blame/unfairness by summing items 3, 7, 9, 10, 11, 23. 2) Severity/irreparability by summing 1, 2, 4, 5, 6, 8. | Baseline, 6 months, 12 months |
| Cognitive function | The Cambridge Neuropsychological Test Automated Battery (CANTAB): Spatial Working Memory, Paired Associates Learning, Delayed Match to Sample and Stocking of Cambridge (SOC). | Baseline, 6 months, 12 months |
| Physical activity level | Accelerometer during one week. Time spent in sedentary, low, moderate and vigorous physical activity. | Baseline, 6 months, 12 months |
| Sleep | Sleep pattern: Actigraph during night and days for one week. | Baseline, 6 months, 12 months |
| Global goal achievement | Self-report. Patient global impression of change (PGIC). The measure reflects participant's beliefs about the efficacy of treatment. The patient rates overall improvement on a 7-point scale where 3 = 'very much improved', 2 = 'much improved', 1 = 'minimally improved', 0 = 'no change', -1 = 'minimally worse', -2 = 'much worse', and -3 ='very much worse'. | 6 months, 12 months, 24 months |
| Explorative identification of change in biomarkers | Biomarkers will be explored by use of the OLINK (name of brand) panel which enables analysis of 92 inflammation-related protein biomarkers. | Changes from baseline to 6 months. |
| Baseline, 6 months, 12 months |
| Self-efficacy to support return to work (employer): Number of items | Study specific questions regarding the employer's self-efficacy to support the employee to return to work. Number of items is tied to individual process analysis of what is required to return to work in each specific case. | Baseline, 6 months |
| Number of participants who report adverse events associated with treatment | Adverse events will be measured with a study-specific diary including a check-list and open ended questions. | Up to 6 months |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |